Famasartan is a new selective AT1 receptor antagonist developed by Baoning pharmaceutical in Korea. It shows rapid and effective antihypertensive effect in many types of hypertension. In September 2010, the South Korean FDA approved the listing, with sales of more than 100 million in 13 years. In 2013, it was listed in Russia, Mexico and Brazil. Preclinical studies show that it is well tolerated. Compared with losartan, it has faster antihypertensive effect and better antihypertensive effect.
